查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933874

全球肌肉骨骼疾病藥物市場（按藥物類別、適應症、給藥途徑、劑型、通路和最終用戶分類）預測（2026-2032年）

Musculoskeletal System Disorder Drug Market by Drug Class, Indication, Route Of Administration, Dosage Form, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肌肉骨骼疾病藥物市場價值將達到 918.3 億美元，到 2026 年將成長至 956.9 億美元，到 2032 年將達到 1,254.8 億美元，複合年成長率為 4.56%。

關鍵市場統計數據
基準年 2025 918.3億美元
預計年份：2026年 956.9億美元
預測年份 2032 1254.8億美元
複合年成長率 (%) 4.56%

對現代醫療保健系統中影響肌肉骨骼藥物的臨床、商業性和運營等方面的演變進行全面概述

肌肉骨骼治療領域正處於快速科學創新、不斷演進的臨床路徑和不斷變化的商業性壓力交匯點，這不僅給整個生態系統中的相關人員帶來了複雜性，也帶來了機會。分子生物學和免疫學的進步催生了新一代標靶治療和生物製藥藥物正在改變臨床醫生治療慢性發炎和退化性疾病的方式。同時，現有治療方法在急性症狀管理和多模式治療方法中仍發揮關鍵作用，凸顯了對產品定位和醫療服務模式進行細緻調整的必要性。

科學創新、支付方變革、數位醫療應用和供應鏈韌性如何融合，重新定義肌肉骨骼治療藥物的研發、取得和交付？

受科學突破、監管環境演變和相關人員期望變化等因素驅動，肌肉骨骼疾病治療領域正經歷著一場變革性的轉變，這些因素重新定義了整個價值鏈中的機會和風險。精準生物製劑和標靶疾病調變器正在改變臨床決策，使表現型特異性介入成為可能，並促使人們重新評估長期疾病管理策略。因此，臨床路徑越來越體現出分層方法，根據分子譜和患者特徵指導治療選擇。

評估2025年關稅環境將如何重塑美國的供應鏈策略、製造地在地化選擇和商業性准入趨勢。

美國在2025年實施的累積關稅，對整個肌肉骨骼治療生態系統的採購、生產和定價策略提出了重要考量。關稅導致進口原料藥、原料和專用包裝成本上漲，擠壓了上游利潤空間，凸顯了供應鏈柔軟性的重要性。為此，製造商正在加速供應商多元化，盡可能將關鍵流程遷回國內，並重新談判供應商契約，以確保供應連續性，同時保護其成本結構。

全面的市場區隔分析揭示了藥物類別、適應症、給藥途徑、劑型、通路和終端用戶環境如何驅動差異化的市場策略。

將肌肉骨骼治療市場按藥物類別細分，可以發現生物製藥、糖皮質激素、緩解疾病抗風濕藥（DMARDs）和非類固醇消炎劑（ NSAIDs）各自擁有不同的臨床和商業路徑，每種藥物都具有獨特的差異化機會和生命週期管理挑戰。生物製藥憑藉其定向機制和長期緩解疾病作用而日益受到關注，而糖皮質非類固醇消炎劑則可在急性發作期迅速緩解症狀。 DMARDs 可作為症狀管理和預防緩解疾病進展之間的橋樑，而 NSAIDs 仍然是多種適應症中症狀管理的核心藥物。這些差異會影響臨床試驗設計、與支付方的互動以及臨床定位。

區域分析比較了美洲、歐洲、中東和非洲以及亞太地區的監管、支付方、製造和需求趨勢。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢表明，創新採納的促進因素、監管複雜性和商業性執行方面存在差異，每個地區在市場准入和規模化方面都有其獨特的考慮因素。在美洲，整合醫療網路和先進的支付系統強調療效比較數據和報銷策略，而集中設立的臨床卓越中心則加速了先進生物製藥和標靶治療的應用。該地區的監管溝通和支付方談判策略通常需要專注於真實世界結果和預算影響評估，以確保患者能夠獲得有利的市場准入。

策略競爭格局概述：概述創新者、生物技術專家、合約研發生產機構 (CDMO) 和分銷合作夥伴如何重塑其在治療領域的勝任力網路和市場領導地位。

肌肉骨骼治療領域的競爭格局由成熟的製藥創新企業、專業生物技術公司、合約研發生產機構（CDMO）和分銷合作夥伴共同塑造，這些企業共同影響著產品的可及性和差異化。擁有深厚臨床開發能力的創新企業往往憑藉其大規模的臨床項目和與關鍵意見領袖（KOL）建立的穩固關係，主導生物製藥和新型分子實體的研發，從而確保產品在專業醫療中心得到應用。生技公司則致力於利基創新和快速迭代開發，包括差異化的作用機制和生物標記主導的研發，這些往往能吸引大型企業的合作或收購意願。

為經營團隊提供可操作的策略議程和營運指南，以整合治療領域的臨床創新、供應鏈韌性和以支付方為中心的商業化。

業界領導者應採取一套切實可行、優先排序的行動方案，將科學創新與商業性可行性、營運韌性和以患者為中心的准入策略相結合。首先，在臨床生命週期的早期階段就應整合證據產生和健康經濟學分析，以支持與支付方的對話並簡化報銷流程。設計以病患相關終點為指標的臨床實驗，並進行評估依從性和生活品質結果的可操作性子研究，將有助於建立更強大的價值提案，並加速藥品納入健保目錄。其次，透過將區域製造地與戰略供應商合作夥伴關係結合，實現供應鏈多元化，從而在維持品質和合規標準的同時，最大限度地降低貿易中斷和關稅風險。

嚴謹的混合研究途徑結合了專家訪談、文獻綜述、監管分析和情境規劃，為切實可行的策略洞察奠定了基礎。

本研究採用混合方法，結合與關鍵相關人員的直接對話、二手文獻回顧、監管分析和定性情境規劃，以全面了解肌肉骨骼藥物的市場趨勢。關鍵資訊來源包括與臨床醫生、支付方、供應鏈管理人員和患者權益組織代表進行的結構化訪談，以獲取關於未滿足的臨床需求、獲取障礙和運營限制的第一手資料。這些訪談有助於建構主題框架，並檢驗貫穿整個分析過程的假設。

結論：整合證據產生、供應鏈靈活性和以患者為中心的商業化對於實現治療益處至關重要。

總之，肌肉骨骼治療領域的特點是科學的快速發展、支付方期望的不斷變化以及營運的複雜性，這些都需要綜合性的策略性應對。生物製藥和標靶治療正在重新定義治療模式，但它們的成功應用取決於可靠的證據、謹慎的定價策略以及完善的生產和分銷基礎設施。關稅和不斷變化的貿易格局使得供應鏈的柔軟性和區域生產考量變得更加重要。同時，數位醫療和患者支援服務仍然是將臨床療效轉化為永續的實際療效的關鍵組成部分。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 肌肉骨骼疾病藥物市場（依藥物類別分類）

  • 生物製藥
  • 皮質類固醇
  • 緩解疾病抗風濕藥物
  • 非類固醇消炎劑

第9章 肌肉骨骼疾病藥物市場（依適應症分類）

  • 僵直性脊椎炎
  • 骨關節炎
  • 乾癬性關節炎
  • 類風濕性關節炎

第10章 肌肉骨骼疾病藥物市場（依給藥途徑分類）

  • 注射
    • 靜脈注射
    • 皮下注射
  • 口服
    • 膠囊
    • 藥片
  • 外用藥物
    • 奶油
    • 凝膠

第11章 肌肉骨骼疾病藥物市場（依劑型分類）

  • 膠囊
  • 凝膠
  • 注射
    • 靜脈注射
    • 皮下注射
  • 藥片

第12章 肌肉骨骼疾病藥物市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 肌肉骨骼疾病藥物市場（依最終用戶分類）

  • 門診手術中心
  • 診所
  • 居家醫療設施
  • 醫院

第14章 各地區肌肉骨骼疾病藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 肌肉骨骼疾病藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國肌肉骨骼疾病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國肌肉骨骼疾病藥物市場

第18章：中國肌肉骨骼疾病藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Horizon Therapeutics plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris
Product Code: MRR-C36616F69998

The Musculoskeletal System Disorder Drug Market was valued at USD 91.83 billion in 2025 and is projected to grow to USD 95.69 billion in 2026, with a CAGR of 4.56%, reaching USD 125.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 91.83 billion
Estimated Year [2026] USD 95.69 billion
Forecast Year [2032] USD 125.48 billion
CAGR (%) 4.56%

A comprehensive orientation to the evolving clinical, commercial, and operational dimensions shaping musculoskeletal disorder therapeutics in modern healthcare systems

The musculoskeletal therapeutics landscape sits at the confluence of rapid scientific innovation, evolving clinical pathways, and shifting commercial pressures, creating both complexity and opportunity for stakeholders across the ecosystem. Advances in molecular biology and immunology have produced a new generation of targeted agents and biologics that are reshaping how clinicians approach chronic inflammatory and degenerative conditions. At the same time, established treatment modalities retain important roles in acute symptom control and multimodal therapy regimens, underscoring the need for nuanced product positioning and care delivery models.

In parallel, payers, providers, and patient advocacy groups increasingly demand evidence of real-world effectiveness and tolerability, prompting sponsors to integrate health economics and outcomes research earlier in development and commercialization planning. As regulatory frameworks adapt to novel modalities and accelerated pathways, market entrants must navigate a more dynamic approval environment while preserving rigorous safety and efficacy standards. Operationally, the supply chain and manufacturing footprint remain decisive factors in product availability and cost management, particularly for complex biologics and parenteral formulations.

Consequently, commercial strategies now require a tighter alignment between clinical value propositions, channel engagement, and patient access programs. This introduction outlines the critical themes that drive the remainder of the executive summary: scientific differentiation, payer and provider interaction, supply chain resilience, and the patient-centric approaches necessary to sustain long-term therapeutic adoption. By framing the landscape in these terms, stakeholders can prioritize investments and organizational capabilities that translate clinical innovation into durable patient benefit and commercial viability.

How scientific innovation, payer evolution, digital health adoption, and supply chain resilience are converging to redefine development, access, and delivery in musculoskeletal therapeutics

The therapeutic landscape for musculoskeletal disorders has undergone transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing stakeholder expectations, each of which has redefined opportunity and risk across the value chain. Precision biologics and targeted disease modulators have altered clinical decision making, enabling phenotype-specific interventions and prompting a reassessment of long-term disease management strategies. As a result, clinical pathways increasingly reflect stratified approaches where molecular profiling and patient characteristics guide therapy selection.

Concurrently, the competitive dynamic has intensified with the entry of biosimilars and next-generation biologics that challenge incumbents on both cost and convenience metrics. Payers have responded by tightening formulary management and shifting toward outcomes-based reimbursement models, thereby elevating the importance of real-world evidence generation and durable patient outcomes. This has spurred closer collaboration between manufacturers and payers to design outcome-linked agreements that mitigate access barriers while sharing performance risk.

Operationally, digital health and telemedicine have become integral to care continuity and adherence management, especially in chronic conditions where remote monitoring reduces the burden of frequent in-person visits. These digital tools also enable richer patient-reported outcomes and adherence data, strengthening value dossiers and post-market surveillance. In addition, supply chain modernization-through regional manufacturing hubs, strategic inventory buffers, and enhanced quality oversight-has emerged as a necessary response to geopolitical disruptions and heightened regulatory scrutiny. Taken together, these shifts demand integrated strategies that align R&D priorities with commercial execution and supply chain resilience, ensuring that clinical advances translate into sustainable therapeutic impact.

Assessing how the 2025 tariff environment has reshaped supply chain strategy, manufacturing localization choices, and commercial access dynamics in the United States

The cumulative tariff actions enacted within the United States in 2025 have introduced material considerations for sourcing, manufacturing, and pricing strategies across the musculoskeletal therapeutics ecosystem. Tariff-driven increases in the cost of imported active pharmaceutical ingredients, raw materials, and specialized packaging have pressured upstream margins and elevated the importance of supply chain flexibility. Manufacturers have responded by accelerating supplier diversification, onshoring critical processes where feasible, and renegotiating supplier contracts to ensure continuity while protecting cost structures.

In addition to input cost impacts, tariff measures have amplified the value of localized manufacturing capabilities for parenteral and biologic products, which depend on complex cold-chain logistics and regulatory compliance frameworks. As companies reassess their manufacturing footprints, they are prioritizing investments that reduce cross-border dependency and shorten lead times. These shifts create both near-term operational costs and long-term strategic benefits in terms of responsiveness to demand fluctuations and mitigation of trade-related risk.

On the commercial front, payers and procurement groups have reacted to cost pressures by intensifying formulary management and exploring contracting innovations that align payment with value delivered. Manufacturers that can demonstrate operational efficiencies, robust supply continuity, and clinically meaningful differentiation have navigated these pressures more successfully. Meanwhile, distributors and specialty pharmacies have adapted inventory management protocols and contingency plans to preserve patient access during periods of supply-chain stress. Ultimately, the 2025 tariff environment underscores the need for integrated commercial, manufacturing, and policy strategies to maintain product availability and protect patient access without eroding long-term innovation incentives.

Holistic segmentation insights revealing how drug class, indication, administration route, dosage form, distribution channels, and end user environments drive differentiated market strategies

Segmenting the musculoskeletal therapeutics market by drug class reveals distinct clinical and commercial pathways for biologics, corticosteroids, disease modifying antirheumatic drugs, and nonsteroidal anti-inflammatory drugs, each presenting unique differentiation opportunities and lifecycle management challenges. Biologics command attention for targeted mechanisms and long-term disease modulation, while corticosteroids offer rapid symptomatic relief in acute flares. Disease modifying antirheumatic drugs occupy a bridge role between symptom control and disease progression prevention, and nonsteroidal anti-inflammatory drugs remain central to symptomatic management across multiple indications. These distinctions influence trial design, payer dialogue, and positioning across care settings.

When viewed through the lens of indication, therapies must be tailored to the pathophysiology and care pathways of ankylosing spondylitis, osteoarthritis, psoriatic arthritis, and rheumatoid arthritis. Each indication brings specific unmet needs and treatment adoption curves; for example, inflammatory arthropathies present opportunities for immunomodulatory agents and biomarkers that predict response, whereas degenerative conditions prioritize symptomatic relief, mobility restoration, and interventions compatible with multimodal care. Route of administration considerations further shape adoption and adherence, with injectable options encompassing intravenous and subcutaneous delivery that often favor clinic-administered dosing and long-acting regimens, while oral formulations in capsule and tablet forms offer convenience but require careful formulation to optimize bioavailability and tolerability. Topical options delivered as creams and gels remain relevant for localized symptom control and for patients seeking non-systemic alternatives.

Dosage form segmentation overlaps with administration routes, highlighting the strategic importance of capsules, gels, injectables, and tablets in product development and positioning. Intravenous and subcutaneous injectables create distinct supply chain and administration requirements, whereas oral dosage forms emphasize patient adherence and pharmacokinetic optimization. Distribution channel dynamics-spanning hospital pharmacies, online pharmacies, and retail pharmacies-affect patient access, reimbursement, and the logistics of specialty products. Finally, end user segmentation across ambulatory surgery centers, clinics, homecare settings, and hospitals determines the operational requirements for product handling, staff training, and patient support services. Integrating these segmentation lenses enables more precise targeting of clinical trials, market access strategies, and patient support initiatives that align product design with real-world care delivery.

Comparative regional analysis describing the distinct regulatory, payer, manufacturing, and demand dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

Regional dynamics exhibit differentiated drivers of innovation adoption, regulatory complexity, and commercial execution across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct considerations for market entry and scale-up. In the Americas, integrated care networks and sophisticated payer systems place a premium on comparative effectiveness data and reimbursement strategy, while concentrated centers of clinical excellence accelerate uptake of advanced biologics and targeted therapies. Regulatory engagement and payer negotiation strategies in this region often need to emphasize real-world outcomes and budget impact assessments to secure favorable access.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and reimbursement pathways requires adaptive market access planning, with some jurisdictions favoring centralized evaluation and others relying on national-level negotiations. Value demonstration and health technology assessment processes are particularly influential in shaping adoption patterns. The region also presents growth opportunities through collaborative procurement and cross-border distribution strategies, though geopolitical and logistics considerations necessitate tailored supply chain arrangements.

Asia-Pacific encompasses a diverse set of markets where demographic shifts, expanding healthcare infrastructure, and growing investment in biopharmaceutical R&D are driving demand for advanced therapeutics. Local manufacturing capabilities and regulatory modernization efforts support faster deployment of complex products, while price sensitivity and evolving payer structures compel manufacturers to balance premium positioning with affordability strategies. Across all regions, alignment of clinical evidence generation, localized commercial models, and manufacturing strategy remains essential to convert scientific innovation into sustained patient access and product uptake.

Strategic competitive overview outlining how innovators, biotech specialists, CDMOs, and distribution partners are reshaping capability networks and market leadership in therapeutics

Competitive positioning within musculoskeletal therapeutics is shaped by a mix of established pharmaceutical innovators, specialized biotech firms, contract development and manufacturing organizations, and distribution partners that together influence product availability and differentiation. Innovator companies with deep clinical development capabilities tend to lead in advancing biologics and novel molecular entities, leveraging large-scale clinical programs and established relationships with key opinion leaders to secure adoption in specialist centers. Biotech firms contribute niche innovation and rapid iteration, often focusing on mechanism-of-action differentiation and biomarker-driven development that can attract partnership or acquisition interest from larger players.

Manufacturing and supply chain partners play a pivotal role for complex parenteral and biologic products, with contract manufacturers and cold-chain logistics providers enabling scalability and regulatory compliance. Organizations that demonstrate strong quality systems and flexible capacity can materially impact time-to-market and mitigate supply disruptions. Meanwhile, specialty pharmacies and distribution networks influence patient access and adherence support, particularly for therapies administered in outpatient or homecare settings. Collaborative models between manufacturers and service providers, including co-developed patient support programs and adherence initiatives, have become important levers to enhance real-world outcomes and sustain product utilization.

Across competitive dynamics, companies that integrate clinical differentiation with pragmatic supply chain and payer engagement strategies gain a durable advantage. Strategic partnerships, licensing agreements, and targeted M&A activity continue to reconfigure capability portfolios, enabling organizations to extend their footprints across therapeutic classes, dosage forms, and end user channels. In this environment, clear articulation of clinical benefit, operational readiness, and evidence generation plans distinguishes market leaders from laggards.

Actionable strategic imperatives and operational playbooks for executives to align clinical innovation, supply chain resilience, and payer-centric commercialization in therapeutics

Industry leaders should adopt a set of practical, prioritized actions that align scientific innovation with commercial execution, operational resilience, and patient-centered access strategies. First, integrate evidence generation and health economics earlier in the clinical lifecycle to support payer dialogue and streamline reimbursement pathways. Designing pivotal trials with patient-relevant endpoints and pragmatic substudies for adherence and quality-of-life outcomes builds a stronger value story and accelerates formulary acceptance. Second, diversify supply chains by combining regional manufacturing hubs with strategic supplier partnerships to minimize exposure to trade disruptions and tariff impacts while preserving quality and compliance standards.

Third, prioritize patient-centric commercialization by expanding support services for adherence, remote monitoring, and home administration where clinically appropriate. These services not only enhance clinical outcomes but also generate real-world data to support ongoing payer negotiations. Fourth, leverage digital platforms to gather longitudinal patient-reported outcomes and to enable adaptive post-market evidence programs that inform label expansions and lifecycle planning. Fifth, pursue flexible pricing and contracting mechanisms, including outcome-based agreements, to align payment with demonstrated patient benefit and to reduce access friction in cost-sensitive environments.

Finally, invest in cross-functional capabilities that bridge R&D, regulatory, commercial, and supply chain teams to ensure rapid operationalization of strategic initiatives. Establishing governance for scenario planning, tariff sensitivity analysis, and rapid commercialization playbooks will enable organizations to respond swiftly to policy changes and competitive moves. Taken together, these actions deliver a balanced approach that protects patient access, preserves innovation economics, and strengthens long-term commercial performance.

A rigorous mixed-methods research approach combining expert interviews, literature review, regulatory analysis, and scenario planning to underpin pragmatic strategic insights

The research integrates a mixed-methods approach combining primary stakeholder engagement, secondary literature synthesis, regulatory analysis, and qualitative scenario planning to produce a robust and defensible view of the musculoskeletal therapeutics landscape. Primary inputs included structured interviews with clinicians, payers, supply chain leaders, and patient advocacy representatives, which provided firsthand perspectives on clinical unmet needs, access barriers, and operational constraints. These interviews informed thematic frameworks and validated assumptions used throughout the analysis.

Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, and public policy documents to ensure that clinical efficacy, safety profiles, and regulatory precedents were accurately reflected. In parallel, competitive intelligence and product pipeline reviews were conducted to map therapeutic differentiation and development trajectories. Supply chain and manufacturing assessments drew on industry best practices and case studies to identify practical mitigation strategies for trade and logistics disruptions. To bolster rigor, findings were subjected to expert panel review and internal quality assurance processes, ensuring that conclusions are grounded in multiple corroborating evidence streams and that analytical limitations are transparently documented.

Finally, scenario-based analyses explored alternative regulatory and policy developments, enabling stakeholders to understand potential operational and commercial outcomes under differing market conditions. This methodological layering ensures the report's conclusions are both actionable and resilient to plausible near-term changes in the therapeutic, regulatory, and trade environments.

Concluding synthesis that distills the imperative for integrated evidence generation, supply chain agility, and patient-centric commercialization to realize therapeutic impact

In conclusion, the musculoskeletal therapeutics arena is characterized by rapid scientific progress, evolving payer expectations, and operational complexities that together demand integrated strategic responses. Biologics and targeted therapies are redefining treatment paradigms, yet their successful adoption depends on robust evidence generation, thoughtful pricing strategies, and reliable manufacturing and distribution infrastructures. Tariff and trade dynamics have heightened the need for supply chain flexibility and regional manufacturing considerations, while digital health and patient support services remain essential to translating clinical efficacy into sustained real-world outcomes.

Organizations that combine clear clinical differentiation with pragmatic operational planning and proactive payer engagement will be best positioned to convert innovation into patient impact and commercial sustainability. Cross-functional collaboration, early health economics integration, and investments in manufacturing and digital capabilities form the backbone of a resilient strategy. As stakeholders navigate this complex environment, maintaining a keen focus on patient-centered value and adaptive execution will determine which therapies achieve broad clinical adoption and deliver measurable improvements in patient lives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Musculoskeletal System Disorder Drug Market, by Drug Class

  • 8.1. Biologics
  • 8.2. Corticosteroids
  • 8.3. Disease Modifying Antirheumatic Drugs
  • 8.4. Nonsteroidal Anti-Inflammatory Drugs

9. Musculoskeletal System Disorder Drug Market, by Indication

  • 9.1. Ankylosing Spondylitis
  • 9.2. Osteoarthritis
  • 9.3. Psoriatic Arthritis
  • 9.4. Rheumatoid Arthritis

10. Musculoskeletal System Disorder Drug Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intravenous
    • 10.1.2. Subcutaneous
  • 10.2. Oral
    • 10.2.1. Capsule
    • 10.2.2. Tablet
  • 10.3. Topical
    • 10.3.1. Cream
    • 10.3.2. Gel

11. Musculoskeletal System Disorder Drug Market, by Dosage Form

  • 11.1. Capsule
  • 11.2. Gel
  • 11.3. Injectable
    • 11.3.1. Intravenous
    • 11.3.2. Subcutaneous
  • 11.4. Tablet

12. Musculoskeletal System Disorder Drug Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Musculoskeletal System Disorder Drug Market, by End User

  • 13.1. Ambulatory Surgery Centers
  • 13.2. Clinics
  • 13.3. Homecare Settings
  • 13.4. Hospitals

14. Musculoskeletal System Disorder Drug Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Musculoskeletal System Disorder Drug Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Musculoskeletal System Disorder Drug Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Musculoskeletal System Disorder Drug Market

18. China Musculoskeletal System Disorder Drug Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Astellas Pharma
  • 19.8. AstraZeneca plc
  • 19.9. Bayer AG
  • 19.10. Biogen Inc.
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Celgene Corporation
  • 19.13. Daiichi Sankyo Company, Ltd.
  • 19.14. Eli Lilly and Company
  • 19.15. Gilead Sciences, Inc.
  • 19.16. GlaxoSmithKline plc
  • 19.17. Horizon Therapeutics plc
  • 19.18. Johnson & Johnson
  • 19.19. Merck & Co., Inc.
  • 19.20. Novartis AG
  • 19.21. Pfizer Inc.
  • 19.22. Regeneron Pharmaceuticals, Inc.
  • 19.23. Roche Holding AG
  • 19.24. Sanofi S.A.
  • 19.25. Sun Pharmaceutical Industries Ltd.
  • 19.26. Takeda Pharmaceutical Company Limited
  • 19.27. Teva Pharmaceutical Industries Ltd.
  • 19.28. UCB S.A.
  • 19.29. Viatris

LIST OF FIGURES

  • FIGURE 1. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 242. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 243. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 244. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 253. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 254. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 255. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 256. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)